The highest approved dose of Mounjaro (tirzepatide), 15 mg per week, produces the greatest average weight loss in clinical trials. But you don’t start there. Every patient begins at 2.5 mg and works up gradually, and the “best” dose for any individual is the one that delivers meaningful results with tolerable side effects.
Weight Loss Results by Dose
The landmark SURMOUNT-1 trial tested tirzepatide at three maintenance doses over 72 weeks in adults with obesity. The results showed a clear dose-dependent pattern: higher doses produced more weight loss.
- 5 mg: 15% body weight loss
- 10 mg: 19.5% body weight loss
- 15 mg: 20.9% body weight loss
- Placebo: 3.1% body weight loss
For someone starting at 250 pounds, those percentages translate to roughly 37.5 pounds on the 5 mg dose, 49 pounds on 10 mg, and 52 pounds on 15 mg. The jump from 5 mg to 10 mg is substantial. The additional benefit of going from 10 mg to 15 mg is smaller, about 1.4 percentage points. That gap matters when you’re weighing extra weight loss against potential side effects.
Why You Can’t Start at the Highest Dose
The FDA-approved starting dose is 2.5 mg once per week, and it’s not considered a treatment dose. It exists purely to let your body adjust. Tirzepatide works by activating two gut hormone pathways that slow digestion, reduce appetite, and change how your body processes blood sugar. Jumping straight to a higher dose would almost certainly cause severe nausea, vomiting, and diarrhea because your digestive system hasn’t adapted yet.
After four weeks at 2.5 mg, you move to 5 mg. From there, your prescriber can increase the dose by 2.5 mg at a time, with at least four weeks between each step. The full climb from 2.5 mg to 15 mg takes a minimum of 20 weeks if you go up at every opportunity. Many people take longer because they pause at a dose that’s working well or need extra time for side effects to settle.
The Three Maintenance Doses
The FDA approves three maintenance doses for weight management: 5 mg, 10 mg, and 15 mg. All three are legitimate long-term options, not just stepping stones to the maximum. Your prescriber will help you find the right level based on how you’re responding.
5 mg
A 15% average weight loss is clinically significant and enough to improve blood pressure, blood sugar, joint pain, and sleep apnea for many people. If you’re losing weight steadily at 5 mg and tolerating it well, there’s no automatic reason to increase. Some people stay here long-term and achieve their goals.
10 mg
This is where most of the additional benefit appears. The jump from 15% to 19.5% average weight loss represents a meaningful increase. For many prescribers, 10 mg is considered a sweet spot: substantially more effective than 5 mg, with side effects that most patients can manage after the adjustment period.
15 mg
The maximum dose edges weight loss slightly higher to about 21% on average. Whether that additional 1.4 percentage points over 10 mg is worth it depends on your individual situation. If your weight loss has stalled at 10 mg and you’re tolerating the medication well, moving to 15 mg is reasonable. If you’re still losing at a steady pace on a lower dose, the extra bump may not justify the increased risk of digestive side effects.
How to Know When to Increase Your Dose
Weight loss plateaus are common at every dose level. Your body adapts, and the rate of loss slows over time. A true plateau, where the scale hasn’t budged for several weeks despite consistent habits, is one reason your prescriber might suggest moving up. But a temporary slowdown doesn’t necessarily mean the dose has stopped working. Weight loss rarely happens in a straight line.
If you’re tolerating your current dose without significant nausea, vomiting, or diarrhea, increasing is generally straightforward. Your prescriber will also confirm your injection technique is correct before assuming the dose itself is the issue. The key rule: never adjust your dose on your own. Each increase needs medical oversight because higher doses carry more potential for gastrointestinal side effects, and there may be other factors worth evaluating first.
Side Effects Increase With Dose
Nausea is the most common side effect across all doses, and it tends to be worst in the first few weeks after each dose increase. Vomiting, diarrhea, constipation, and reduced appetite are also common. These effects are directly related to how the drug slows stomach emptying and signals fullness to the brain.
Most people find that side effects improve over time at each dose level, which is why the gradual titration schedule exists. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help during the adjustment period. For some people, the side effects at higher doses are severe enough that staying at a lower, better-tolerated dose makes more sense even if it means slightly less weight loss on paper.
Staying on Treatment Long-Term
Obesity is a chronic condition, and the weight loss from tirzepatide depends on continued treatment. Research shows that stopping the medication leads to significant weight regain in most people. The American College of Gastroenterology notes that continued treatment is generally necessary to maintain results, though the lowest effective dose should be used.
This is another reason to think carefully about dose selection. The “best” dose isn’t necessarily the one that produces the most dramatic number on a clinical trial chart. It’s the dose you can sustain over years while maintaining a good quality of life. If 10 mg keeps you at a healthy weight with minimal side effects, that’s a better long-term choice than 15 mg with persistent nausea that makes you want to quit.
What Makes Mounjaro Different
Tirzepatide targets two hormone pathways instead of one. Older weight loss medications like semaglutide (Wegovy, Ozempic) activate only GLP-1 receptors, which slow digestion and reduce appetite. Tirzepatide also activates GIP receptors, which appear to improve how your body handles insulin through a separate mechanism. This dual action is thought to explain why tirzepatide’s weight loss numbers in trials have been higher than those seen with GLP-1-only drugs, though direct head-to-head comparisons in obesity-specific trials are still limited.